# US 2003/0203360 A1 · Methods for identifying products employing gene expression

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0203360 A1
- Document ID: US20030203360A1
- Status: Published application
- Kind: A1
- Application number: 09/950,312
- Filed: 2001-09-10
- Published: 2003-10-30
- Earliest claimed: 2000-10-17
- Inventors: Barry Weinstein; Lorraine Holowach Keller; Subba Reddy Palli
- Web page: https://patentgrep.com/patent/US20030203360A1

## CPC

- C12Q 1/6897: involving reporter genes operably linked to promoters
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

A method for identifying a product involves the steps of: (1) associating with the product a marker ligand; and (2) detecting the marker ligand in the product at a later point in time as a means of identifying the product by contacting the product with a detector composition. The detector composition comprises one or more first nucleotide sequences encoding one or more natural or synthetic ligand-dependent transcription factors, wherein said factors comprise at least one ligand binding domain, at least one DNA binding domain and at least one transactivation domain; and a second nucleotide sequence encoding a reporter gene under the regulatory control of a receptor response element or a modified or synthetic response element, and a second promoter. The method may also employ a corepressor or coactivator or a nucleotide sequence encoding the corepressor or activator. Interaction between the marker ligand and ligand binding domain is highly specific and induces a change in the expression of the reporter gene, the change producing a detectable signal identifying the presence of the marker ligand in the product. The detector composition, a cell line containing the first and second nucleotide sequences, kits using them and products marked with specific marker ligands are useful in this method.

## Claims

### Claim 1

A method for identifying a product, said method comprising the steps of:
(a) associating with said product a marker ligand;
(b) detecting said marker ligand in said product, a portion of said product or an extract of said product at a later point in time as a means of identifying the product by contacting said product with a composition comprising
(1) one or more first nucleotide sequences encoding one or more natural or synthetic ligand-dependent transcription factors, wherein said factors comprise at least one ligand binding domain, at least one DNA binding domain and at least one transactivation domain; and
(2) a second nucleotide sequence encoding a reporter gene under the regulatory control of a receptor response element or a modified or synthetic response element, and a second promoter;
wherein the interaction between said marker ligand and said at least one ligand binding domain is highly specific and induces a change in the expression of said reporter gene, said change producing a detectable signal identifying the presence of said ligand in said product.

### Claim 2 (depends on 1)

The method according to claim 1, wherein said transcription factor is under the regulatory control of a first promoter.

### Claim 3 (depends on 1)

The method according to claim 1, wherein said transactivation domain is a carboxy terminal portion of a ligand binding domain that enhances activation.

### Claim 4 (depends on 1)

The method according to claim 1, wherein said transactivation domain is a sequence independent of said ligand binding domain.

### Claim 5 (depends on 1)

The method according to claim 1, wherein said composition further comprises a third nucleotide sequence encoding a coactivator or corepressor that interacts with the ligand-dependent transcription factor to activate or repress expression of said reporter gene.

### Claim 6 (depends on 1)

The method according to claim 1, wherein said product is contacted with a coactivator or repressor protein that interacts with the ligand-dependent transcription factor to activate or repress expression of said reporter gene.

### Claim 7 (depends on 1)

The method according to claim 1, wherein said ligand dependent transcription factor is a nuclear receptor superfamily protein or functional fragment thereof.

### Claim 8 (depends on 1)

The method according to claim 1, wherein said ligand dependent transcription factor is a modified or synthetic protein having the transcription activating properties of a nuclear receptor superfamily protein.

### Claim 9 (depends on 7)

The method according to claim 7 wherein said factor is a modified insect nuclear receptor superfamily protein.

### Claim 10 (depends on 7)

The method according to claim 7, wherein said factor is selected from the group of nuclear receptor superfamily members consisting of ecdysone, estrogen, retinoid X, progesterone, glucocorticoid, vitamin D, retinoic acid, and peroxisome proliferation receptor protein.

### Claim 11 (depends on 1)

The method according to claim 1, wherein said factor is selected from a tetracycline inducible lac operon and an IPTG inducible receptor protein, a lactone receptor protein, and an arabinose-inducible protein.

### Claim 12 (depends on 1)

The method according to claim 1, wherein said composition is a cell comprising said first nucleotide sequence and said second nucleotide sequence.

### Claim 13 (depends on 12)

The method according to claim 12, wherein said cell is a eukaryotic cell.

### Claim 14 (depends on 12)

The method according to claim 12, wherein said cell is a prokaryotic cell.

### Claim 15 (depends on 12)

The method according to claim 12, wherein said cell is immobilized on a solid support.

### Claim 16 (depends on 1)

The method according to claim 1, wherein said binding of said marker ligand to said ligand binding domain triggers the binding of the DNA binding domain to said response element, wherein said bound response element activates or suppresses the expression of said reporter gene.

### Claim 17 (depends on 1)

The method according to claim 1, wherein said composition contains multiple different ligand binding domains, which associate to provide a single receptor.

### Claim at position 18 (depends on 1)

18 The method according to claim 1, wherein said composition contains a single ligand binding domain.

### Claim 19 (depends on 1)

The method according to claim 1, wherein said ligand binding domain is selected from the group consisting of the ligand binding domain from a steroid/thyroid nuclear receptor superfamily member, a synthetic or recombinantly modified domain thereof, a fragment of said domain, and an analog thereof.

### Claim 20 (depends on 1)

The method according to claim 1, wherein said DNA binding domain mediates binding of said ligand-dependent transcription factor to said response element of said second nucleotide sequence.

### Claim 21 (depends on 20)

The method according to claim 20, wherein said DNA binding domain is heterologous to said ligand binding domain.

### Claim 22 (depends on 20)

The method according to claim 20, wherein said DNA binding domain is selected from the group consisting of a DNA binding domain of GAL4, a DNA binding domain of LexA, a DNA binding domain from a transcription factor; a DNA binding domain from a steroid/thyroid nuclear receptor superfamily member, a DNA binding domain from a bacterial LacZ, a DNA binding domain from a yeast cell, a DNA binding domain from a plant cell, a DNA binding domain from a virus, an artificial zinc finger region, a synthetic or recombinant analog, combination or modification thereof.

### Claim 23 (depends on 1)

The method according to claim 1, wherein said transactivation domain amplifies a conformational change in the ligand dependent transcription factor when the ligand binds to said ligand binding domain.

### Claim 24 (depends on 23)

The method according to claim 23, wherein said transactivation domain is selected from the group consisting of a steroid/thyroid hormone nuclear receptor activation domain, a synthetic or chimeric activation domain, a polyglutamine activation domain, basic or acidic amino acid activation domain, a viral activation domain, a plant virus activation domain, or the VP16, GAL4, NF-kB, or BP64 activation domain, a modified activation domain, a fragment of any of said activation domains and a modification thereof.

### Claim 25 (depends on 24)

The method according to claim 24, wherein more than one activation domain is employed to increase the strength of activation.

### Claim 26 (depends on 1)

The method according to claim 1, wherein said response element is selected from the group consisting of a response element from GAL4, a response element from a steroid/thyroid hormone nuclear receptor, an artificial zinc finger, a LexA operon, a lac operon response element, and a synthetic or recombinantly produced response element that recognizes a DNA binding domain.

### Claim 27 (depends on 1)

The method according to claim 1, wherein said first promoter regulates the expression of said factor in a selected host cell or virus.

### Claim 28 (depends on 2)

The method according to claim 2, wherein said first promoter is a constitutive promoter.

### Claim 29 (depends on 1)

The method according to claim 1, wherein said second promoter regulates the inducible expression of said reporter in the selected host cell and initiates or suppresses transcription of said reporter gene only in the presence of a complex formed by the marker ligand, the ligand-dependent transcription factor, and said response element.

### Claim 30 (depends on 2)

The method according to claim 2, wherein said first and second promoter are the same.

### Claim 31 (depends on 30)

The method according to claim 30, wherein said second promoter is an inducible promoter.

### Claim 32 (depends on 1)

The method according to claim 1 wherein the signal produced by said reporter gene is detectable by a method selected from the group consisting of visual detection, microscopic detection, ultraviolet light detection, electrical detection, change in capacitance, hybridization, infrared detection, fluorescence detection and nuclear magnetic resonance.

### Claim 33 (depends on 32)

The method according to claim 32, wherein said reporter gene is a gene encoding a fluorescent or luminescent protein.

### Claim 34 (depends on 32)

The method according to claim 32, wherein said reporter gene encodes a protein that interacts with a substrate to produce a detectable signal.

### Claim 35 (depends on 32)

The method according to claim 32, wherein said reporter gene causes directly or indirectly a red or blue shift in the emission spectrum of said detectable signal.

### Claim 36 (depends on 34)

The method according to claim 34, wherein said protein is an enzyme that can catalyze a detectable signal.

### Claim 37 (depends on 1)

The method according to claim 1, wherein said marker ligand is a molecule that specifically binds to said ligand binding domain.

### Claim 38 (depends on 37)

The method according to claim 37 wherein said marker ligand is a small molecule that can specifically interact with a selected ligand binding domain.

### Claim 39 (depends on 35)

The method according to claim 35, wherein said ligand is a synthetic chemical compound.

### Claim 40 (depends on 38)

The method according to claim 38, wherein said marker ligand is selected from the group consisting of ponasteroneA, muristerone A, an alkylhydrazine, an N,N′-diacylhydrazine, an N-substituted-N,N′ diacylhydrazine, an N-substituted-N,N′-disubstituted hydrazine, a dibenzoylalkyl cyanohydrazine, an N-alkyl-N,N′-diaroylhydrazine, an N-acyl-N-alkyl-N′-aroylhydrazine, a 3,5-di-tert-butyl-r-hydroxy-N-isobutyl-benzamide, and an 8-O-acetylharpagide.

### Claim 41 (depends on 1)

The method according to claim 1, wherein said product is selected from the group consisting of a liquid, a solid, a dispersion, an emulsion, and a latex.

### Claim 42 (depends on 41)

The method according to claim 41, wherein said marker ligand is admixed directly into said product.

### Claim 43 (depends on 41)

The method according to claim 41, wherein the product is a solid and the marker ligand is applied to the surface of the product, or to a tag or packaging associated with the product.

### Claim 44 (depends on 41)

The method according to claim 41, wherein said ligand is present in said liquid product at a concentration of between 0.1 to 10 parts per billion.

### Claim 45 (depends on 41)

The method according to claim 41, wherein said ligand is present in said solid product at a concentration of between 10 to about 500 parts per billion.

### Claim 46

A marked product comprising a liquid, a solid, a dispersion, an emulsion, or a latex associated with a marker ligand selected from the group consisting of ponasterone A, muristerone A, an alkylhydrazine, an N,N′-diacylhydrazine, an N-substituted-N,N′ diacylhydrazine, an N-substituted-N,N′-disubstituted hydrazine, a dibenzoylalkyl cyanohydrazine, an N-alkyl-N,N′-diaroylhydrazine, an N-acyl-N-alkyl-N′-aroylhydrazine, a 3,5-di-tert-butyl-r-hydroxy-N-isobutyl-benzamide, and an 8-O-acetylharpagide.

### Claim 47

One or more cells comprising:
(a) one or more first nucleotide sequences encoding one or more natural or synthetic ligand-dependent transcription factors, wherein said factors comprise at least one ligand binding domain, at least one DNA binding domain and at least one transactivation domain; and
(b) a second nucleotide sequence encoding a reporter gene under the regulatory control of a receptor response element or a modified or synthetic response element, and a second promoter;
wherein interaction between said marker ligand and said at least one ligand binding domain is highly specific and induces a change in the expression of said reporter gene, said change producing a detectable signal identifying the presence of said marker ligand.

### Claim 48

A kit for identifying a marked product comprising:
(a) a detector composition comprising
(1) one or more first nucleotide sequences encoding one or more natural or synthetic ligand-dependent transcription factors, wherein said factors comprise at least one ligand binding domain, at least one DNA binding domain and at least one transactivation domain; and
(2) a second nucleotide sequence encoding a reporter gene under the regulatory control of a receptor response element or a modified or synthetic response element, and a second promoter;
wherein interaction between said marker ligand and said at least one ligand binding domain is highly specific and induces a change in the expression of said reporter gene, said change producing a detectable signal identifying the presence of said marker ligand; and
(b) means for detecting and measuring said signal.

### Claim 49 (depends on 48)

The kit according to claim 48, wherein said composition (a) is selected from the group consisting of one or more cells and one or more lyophilized cells.

### Claim 50 (depends on 48)

The kit according to claim 48, further comprising at least one component selected from the group consisting of reagents necessary to culture said one or more cells, reagents necessary to reactivate said one or more lyophilized cells or cell lysates; instructions for performing a detection assay, substrates to which the composition has been pre-adsorbed in a lyophilized state, diluents and buffers, indicator charts for signal comparisons, disposable gloves, decontamination instructions, applicator sticks or containers, and sample preparator cups.

### Claim 51

A detector composition comprising:
(a) a live cell comprising:
(1) one or more first nucleotide sequences encoding one or more natural or synthetic ligand-dependent transcription factors, wherein said factors comprise at least one ligand binding domain, at least one DNA binding domain and at least one transactivation domain; and
(2) a second nucleotide sequence encoding a reporter gene under the regulatory control of a receptor response element or a modified or synthetic response element, and a second promoter;
wherein interaction between said marker ligand and said at least one ligand binding domain is highly specific and induces a change in the expression of said reporter gene, said change producing a detectable signal identifying the presence of said marker ligand; and
(b) a solid support upon which said cell is immobilized.

### Claim 52 (depends on 51)

The composition according to claim 51, wherein said support is selected from the group consisting of a microcell, a microcapsule, a microtiter plate, a bead, and a biochip.

### Claim 53 (depends on 51)

The composition according to claim 51, wherein said one or more cell is lyophilized.
